Article Text

Download PDFPDF
Standard medical care does not offer sufficient relief of non-specific chest pain leading to additional diagnostic testing of no clinical benefit
  1. Clare J Taylor,
  2. Richard J McManus
  1. Primary Care Clinical Sciences, University of Birmingham, Birmingham, UK
  1. Correspondence to Clare J Taylor
    Primary Care Clinical Sciences, Primary Care Clinical Sciences Building, University of Birmingham, Birmingham B15 2TT, UK; c.j.taylor.1{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Commentary on:

Chest pain – a common and persistent problem

Chest pain is a common presenting complaint in patients in primary and secondary care. Serious underlying cardiovascular pathology such as coronary heart disease should be ruled out, but the cause of chest pain in primary care is most often not cardiac.1 Respiratory, gastrointestinal or musculoskeletal disorders also present with chest pain, and a significant proportion of patients do not have any identifiable underlying physical cause.2

Glombiewski and colleagues present a prospective physician-based cohort study from Germany that examined symptom persistence at 6 months, investigation and onward referral in patients with non-specific chest pain. A total of 755 patients over the age of 35 years presenting with non-specific chest pain (defined as pain localised in the area between the clavicles and lower costal margins and anterior to the posterior axillary lines) were followed up at 6 weeks …

View Full Text


  • Competing interests RJM has participated in research funded by Pfizer, Sanofi Aventis and A. Menarini Pharma. He has received funding to attend a research conference from MSD and consultancy fees from Tplus Medical. He is funded by a National Institute for Health Research Career Development Fellowship. CJT has participated in research funded by Sanofi Aventis. CJT is funded by a National Institute for Health Research In-Practice Fellowship.